Published October 15, 2014 | Version v1
Journal article

Preclinical pharmacology and toxicology study of Ad-hTERT-E1a-Apoptin, a novel dual cancer-specific oncolytic adenovirus

  • 1. Institute of Military Veterinary, Academy of Military Medical Sciences of PLA, Changchun 130122 (China)
  • 2. State Key Laboratory of Polymer Physics and Chemistry, Changchun Institute of Applied Chemistry, Chinese Academy of Sciences, Changchun 130022 (China)
  • 3. Changchun Brother Biotech Co., Ltd., Changchun, 130000 (China)
  • 4. The Key Laboratory of Jilin Province for Zoonosis Prevention and Control, Changchun 130122 (China)
  • 5. School of Clinical Medicine, Jilin University, Changchun 130001 (China)
  • 6. Affiliated Hospital of Changchun University of Traditional Chinese Medicine, Changchun 130021 (China)
  • 7. Department of Head and Neck Surgery, Tumor Hospital of Jilin Province, Changchun 130012 (China)

Description

Clinical studies have demonstrated that conditionally replicating adenovirus is safe. We constructed an oncolytic adenovirus, Ad-hTERT-E1a-Apoptin, using a cancer-specific promoter (human telomerase reverse transcriptase promoter, hTERTp) and a cancer cell-selective apoptosis-inducing gene (Apoptin). Ad-hTERT-E1a-Apoptin was proven effective both in vitro and in vivo in our previous study. In this study, the preclinical safety profiles of Ad-hTERT-E1a-Apoptin in animal models were investigated. At doses of 5.0 × 108, 2.5 × 109, and 1.25 × 1010 viral particles (VP)/kg, Ad-hTERT-E1a-Apoptin had no adverse effects on mouse behavior, muscle cooperation, sedative effect, digestive system, and nervous systems, or on beagle cardiovascular and respiratory systems at 5.0 × 108, 2.5 × 109, and 1.25 × 1010 VP/kg doses. In acute toxicity tests in mice, the maximum tolerated dose > 5 × 1010 VP/kg. There was no inflammation or ulceration at the injection sites within two weeks. In repeat-dose toxicological studies, the no observable adverse effect levels of Ad-hTERT-E1a-Apoptin in rats (1.25 × 1010 VP/kg) and beagles (2.5 × 109 VP/kg) were 62.5- and 12.5-fold of the proposed clinical dose, respectively. The anti-virus antibody was produced in animal sera. Bone marrow examination revealed no histopathological changes. Guinea pigs sensitized by three repeated intraperitoneal injections of 1.35 × 1010 VP/mL Ad-hTERT-E1a-Apoptin each and challenged by one intravenous injection of 1.67 × 108 VP/kg Ad-hTERT-E1a-Apoptin did not exhibit any sign of systemic anaphylaxis. Our data from different animal models suggest that Ad-hTERT-E1a-Apoptin is a safe anti-tumor therapeutic agent. - Highlights: • We use the rodents and non-rodents animal models to evaluation Ad-hTERT-E1a-Apoptin. • Ad-hTERT-E1a-Apoptin is a safe anti-tumor therapeutic agent. • Demonstrate the safety and feasibility dose of injected Ad-hTERT-E1a-Apoptin

Availability note (English)

Available from http://dx.doi.org/10.1016/j.taap.2014.08.008

Additional details

Identifiers

DOI
10.1016/j.taap.2014.08.008;
PII
S0041-008X(14)00300-7;

Publishing Information

Journal Title
Toxicology and Applied Pharmacology
Journal Volume
280
Journal Issue
2
Journal Page Range
p. 362-369
ISSN
0041-008X
CODEN
TXAPA9

Optional Information

Copyright
Copyright (c) 2014 Elsevier Science B.V., Amsterdam, The Netherlands, All rights reserved.